Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has made advancements on its work on a proprietary yeast strain for the production of Tetrahydrocannabinol (“THC”); the company also announced plans to commercially launch the product in the highly regulated, legal Canadian market. Willow’s Canadian-based R&D (“R&D”) team has developed a proprietary yeast strain along with a process to produce THC; the company is eyeing a pilot scale run by the end of 2021. Willow is operating under the believe that a significant number of consumer product manufacturers are looking for a consistent, high-purity, odorless, flavorless THC ingredient, which is exactly what it is producing. Willow expects the product to be used in the 2.0 market, which includes vapes, edibles, beverages, concentrates and topicals, and has been identified as a multibillion-dollar industry. Willow also announced that it has found a development partner for product isolation, purification and scale up to pilot; in addition, the company is talking with potential manufacturing companies. “We are excited to announce our proprietary THC yeast biosynthesis production process for launch in the Canadian market,” said Willow president and CEO Trevor Peters in the press release. “Our platform technology enables us to produce a variety of cannabinoids and leverage our previous work on CBG. From conversations with prospective customers in Canada , we believe that there is significant demand for consistent, high-purity THC. The flavorless, odorless attributes of our finished product make it suitable as a core ingredient for the cannabis 2.0 market in Canada . There is also strong demand for a more sustainable and environmentally friendly way to produce THC. Our manufacturing process is 50 to 500 times more efficient than indoor cultivation and is the next evolution of sustainable cannabinoid manufacturing.”
To view the full press release, visit https://www.cnw.fm/RYnjb
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Vancouver, British Columbia, which produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is on the production of cannabinoids for the treatment for pain, anxiety, obesity and brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life-changing drugs. For more information about the company, visit www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://cnw.fm/WLLW
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
